KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Management of Marginal Zone Lymphoma: A Canadian Perspective.

Anthea Peters, Mary-Margaret Keating, Anna Nikonova, Sarah Doucette, Anca Prica

Curr Oncol 30(2) 1745-1759

PMID36826096
PMCIDPMC9955247
DOI10.3390/curroncol30020135
发表日期2023-02-24
摘要

摘要

Marginal zone lymphomas (MZL) are a rare, heterogenous group of lymphomas, accounting for 5-17% of indolent non-Hodgkin lymphomas in the western world. They can be further divided into three subtypes: extranodal MZL, splenic MZL, and nodal MZL. These subtypes differ in clinical presentation and behavior, which influences how they are managed. There is currently no standard of care for the treatment of MZL, owing to the difficulty in conducting phase 3 randomized trials in MZL, and the fact that there are limited data on the efficacy of therapy in individual subtypes. Treatment practices are thus largely borrowed from other indolent lymphomas and are based on patient and disease characteristics, as well as access to therapy. This review summarizes the Canadian treatment landscape for MZL and how these therapies may be sequenced in practice.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。